# A First-in-human Study to Investigate the Safety, Tolerability and Pharmacokinetics of MAS825 in Healthy Volunteers

> **NCT04665154** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 80 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** MAS825
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04665154
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-07
- **Primary completion:** 2022-08-03
- **Final completion:** 2022-08-03
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2022-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04665154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04665154, "A First-in-human Study to Investigate the Safety, Tolerability and Pharmacokinetics of MAS825 in Healthy Volunteers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04665154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*